v3.25.4
STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Liminatus Pharma, LLC    
Operating expenses:    
General and administrative $ 645,000 $ 1,062,000
Research and development 2,685,000 3,757,000
Total operating expenses 3,330,000 4,819,000
Loss from operations (3,330,000) (4,819,000)
Other income (expense):    
Interest expense, related parties (339,000) (175,000)
Interest income 123,000 10,000
Total other income (expense), net (216,000) (165,000)
Net loss (3,546,000) (4,984,000)
Class A Member Units | Liminatus Pharma, LLC    
Other income (expense):    
Net loss $ (1,738,000) $ (2,442,000)
Net loss per unit, basic (In dollars per unit) $ (0.02) $ (0.03)
Net loss per unit, diluted (In dollars per unit) $ (0.02) $ (0.03)
Weighted average units outstanding, basic (In shares) 95,555,554 85,825,570
Weighted average units outstanding, diluted (In shares) 95,555,554 85,825,570
Class B Member Units | Liminatus Pharma, LLC    
Other income (expense):    
Net loss $ (1,808,000) $ (2,542,000)
Net loss per unit, basic (In dollars per unit) $ (0.11) $ (0.15)
Net loss per unit, diluted (In dollars per unit) $ (0.11) $ (0.15)
Weighted average units outstanding, basic (In shares) 16,666,666 16,666,666
Weighted average units outstanding, diluted (In shares) 16,666,666 16,666,666